Literature DB >> 1898253

Altered serotonergic and cholinergic synaptic markers in Pick's disease.

D L Sparks1, W R Markesbery.   

Abstract

Choline acetyltransferase and acetylcholinesterase activities as well as serotonin and imipramine binding were determined in the hypothalamus, nucleus basalis of Meynert, and frontal and temporal poles of subjects with Pick's disease. Choline acetyltransferase activity was decreased in the hypothalamus and nucleus basalis of Meynert, and acetylcholinesterase activity was decreased in the nucleus basalis of Meynert only. Serotonin binding was decreased in all sites but the nucleus basalis of Meynert, and imipramine binding was altered only in the frontal pole. Comparison with previous reports of Alzheimer's disease indicates that with respect to these synaptic markers, Alzheimer's disease and Pick's disease are not similar.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1898253     DOI： 10.1001/archneur.1991.00530200032014

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


  27 in total

1.  Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration.

Authors:  Tiffany W Chow; Mario F Mendez
Journal:  Am J Alzheimers Dis Other Demen       Date:  2002 Sep-Oct       Impact factor: 2.035

2.  Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer's disease.

Authors:  M Ikeda; J Brown; A J Holland; R Fukuhara; J R Hodges
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-10       Impact factor: 10.154

Review 3.  Non-pharmacological Management of Behavioral Symptoms in Frontotemporal and Other Dementias.

Authors:  Cynthia Barton; Robin Ketelle; Jennifer Merrilees; Bruce Miller
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

Review 4.  Treatment approaches to symptoms associated with frontotemporal degeneration.

Authors:  Tiffany W Chow
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

Review 5.  Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia.

Authors:  Geoffrey A Kerchner; Maria Carmela Tartaglia; Adam Boxer
Journal:  Expert Rev Neurother       Date:  2011-05       Impact factor: 4.618

Review 6.  [Frontotemporal dementias].

Authors:  K Witt; G Deuschl; T Bartsch
Journal:  Nervenarzt       Date:  2013-01       Impact factor: 1.214

7.  MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia.

Authors:  Haruo Hanyu; Tetsuichi Asano; Hirofumi Sakurai; Yuriko Tanaka; Masaru Takasaki; Kimihiko Abe
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

Review 8.  Is synaptic loss a unique hallmark of Alzheimer's disease?

Authors:  Stephen W Scheff; Janna H Neltner; Peter T Nelson
Journal:  Biochem Pharmacol       Date:  2014-01-09       Impact factor: 5.858

Review 9.  Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management.

Authors:  Gil D Rabinovici; Bruce L Miller
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

10.  Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial.

Authors:  J B Deakin; S Rahman; P J Nestor; J R Hodges; B J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2003-12-10       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.